UBS Group’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-5,269
| Closed | -$3.85K | – | 10955 |
|
|
2026
Q1 | $3.85K | Sell |
5,269
-12,704
| -71% | -$57.8K | ﹤0.01% | 9026 |
|
|
2025
Q4 | $100K | Buy |
+17,973
| New | +$200K | ﹤0.01% | 6911 |
|
|
2025
Q3 | – | Sell |
-10
| Closed | -$76 | – | 10844 |
|
|
2025
Q2 | $76 | Sell |
10
-11,167
| -100% | -$174K | ﹤0.01% | 10025 |
|
|
2025
Q1 | $213K | Buy |
+11,177
| New | +$351K | ﹤0.01% | 6514 |
|
|
2024
Q4 | – | Sell |
-116
| Closed | -$3.33K | – | 10330 |
|
|
2024
Q3 | $3.33K | Sell |
116
-6,506
| -98% | -$145K | ﹤0.01% | 8284 |
|
|
2024
Q2 | $170K | Buy |
6,622
+6,217
| +1,535% | +$283K | ﹤0.01% | 5777 |
|
|
2024
Q1 | $30.6K | Buy |
+405
| New | +$32.1K | ﹤0.01% | 6734 |
|
|
2022
Q1 | – | Sell |
-98
| Closed | -$6K | – | 10811 |
|
|
2021
Q4 | $6K | Buy |
98
+19
| +24% | +$1.35K | ﹤0.01% | 9291 |
|
|
2021
Q3 | $6K | Sell |
79
-23
| -23% | -$1.81K | ﹤0.01% | 8440 |
|
|
2021
Q2 | $10K | Buy |
+102
| New | +$10.3K | ﹤0.01% | 8059 |
|
|
2021
Q1 | – | Sell |
-86
| Closed | -$15K | – | 9402 |
|
|
2020
Q4 | $15K | Buy |
86
+85
| +8,500% | +$17.2K | ﹤0.01% | 7173 |
|
|
2020
Q3 | $0 | Sell |
1
-23
| -96% | -$4.96K | ﹤0.01% | 8352 |
|
|
2020
Q2 | $5K | Buy |
24
+2
| +9% | +$426 | ﹤0.01% | 7384 |
|
|
2020
Q1 | $5K | Sell |
22
-95
| -81% | -$19.9K | ﹤0.01% | 7317 |
|
|
2019
Q4 | $25K | Hold |
117
| – | – | ﹤0.01% | 6753 |
|
|
2019
Q3 | $24K | Buy |
117
+62
| +113% | +$12.8K | ﹤0.01% | 6635 |
|
|
2019
Q2 | $11K | Hold |
55
| – | – | ﹤0.01% | 7022 |
|
|
2019
Q1 | $11K | Buy |
+55
| New | +$11K | ﹤0.01% | 6756 |
|
Other funds holding RVPH
UBS Group's RVPH Position: Q2 2026 in Review
UBS Group sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q2 2026, closing a stake of 5,269 shares — an estimated $3.85K sold.
UBS Group first reported a position in RVPH in Q1 2019 and held it in 18 quarters. The position peaked at $213K in Q1 2025. 5 funds tracked by Wall St. Rank hold RVPH as of Q2 2026.
- UBS Group reported no remaining REVIVA PHARMA HLDGS INC position as of Q2 2026 after selling out during the quarter.
- UBS Group sold 5,269 REVIVA PHARMA HLDGS INC shares in Q2 2026, an estimated $3.85K.
- UBS Group first reported a position in REVIVA PHARMA HLDGS INC in Q1 2019 and held it in 18 quarters.
- UBS Group's REVIVA PHARMA HLDGS INC position peaked at $213K in Q1 2025.
- 5 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.